{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T19:08:43Z","timestamp":1790536123637,"version":"4.1.0"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>In October 2021, the FDA approved brexucabtagene autoleucel (brexu-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (B-ALL). Approval was based on the phase II portion of ZUMA-3, a single-arm, open-label, multicenter trial that evaluated a single infusion of brexu-cel, preceded by lymphodepleting chemotherapy with cyclophosphamide and fludarabine, in this population. Efficacy was established on the basis of complete remission (CR) within 3 months after infusion and the duration of CR (DOCR). Among 54 patients in the efficacy analysis population, the CR rate was 52% (95% CI: 38, 66) with a median time-to-response of 56 days. With a median follow-up for responders of 7.1 months, the median DOCR was not reached. For all leukapheresed patients in the phase II portion of this trial (n = 71), the CR rate was 41% (95% CI: 29, 53). Among the 78 patients treated with the approved dose of brexu-cel, serious adverse reactions occurred in 79% and fatal adverse reactions occurred in 5% and included cerebral edema and infections. Cytokine release syndrome occurred in 92% (grade \u22653, 26%) and neurologic toxicities occurred in 87% (grade \u22653, 35%), leading to implementation of a risk evaluation and mitigation strategy (REMS). Postmarketing study with 15 years of follow-up will further evaluate long-term safety in adult patients with relapsed or refractory B-ALL.<\/jats:p>","DOI":"10.1093\/oncolo\/oyac163","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T11:18:08Z","timestamp":1660907888000},"page":"892-899","source":"Crossref","is-referenced-by-count":56,"title":["FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia"],"prefix":"10.1093","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3357-6941","authenticated-orcid":false,"given":"Najat","family":"Bouchkouj","sequence":"first","affiliation":[{"name":"Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Lin","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Wang","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Przepiorka","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Xu","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejashri","family":"Purohit-Sheth","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Theoret","sequence":"additional","affiliation":[{"name":"Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring , MD , USA"},{"name":"Oncology Center of Excellence, U.S. Food and Drug Administration, Silver Spring , MD , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"issue":"12","key":"2022100119165777800_CIT0001","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.3324\/haematol.2016.144311","article-title":"International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed\/refractory acute lymphoblastic leukemia","volume":"101","author":"G\u00f6kbuget","year":"2016","journal-title":"Haematologica"},{"issue":"10","key":"2022100119165777800_CIT0002","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1182\/blood-2011-12-399287","article-title":"Outcome of relapsed adult lymphoblastic leukemia depends son response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2022100119165777800_CIT0003","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory b-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O'Leary","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10299","key":"2022100119165777800_CIT0004","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"2022100119165777800_CIT0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2020009098","article-title":"KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed\/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results","volume":"138","author":"Shah","year":"2021","journal-title":"Blood"},{"key":"2022100119165777800_CIT0006","author":"Bouchkouj","year":"2021"},{"issue":"2","key":"2022100119165777800_CIT0007","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2022100119165777800_CIT0008","volume-title":"Clinical Pharmacology Review Memo (BLA 125703\/91)","author":"Wang","year":"2021"},{"key":"2022100119165777800_CIT0009","volume-title":"US Prescribing Information for KYMRIAH (tisagenlecleucel)"},{"issue":"9","key":"2022100119165777800_CIT0010","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1111\/bcp.14281","article-title":"Chimeric antigen receptor T-cell therapies: optimising the dose","volume":"86","author":"Dasyam","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2022100119165777800_CIT0011","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/psp4.12598","article-title":"Bench-to-bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic-pharmacodynamic model: A case study with anti-BCMA CAR-T","volume":"10","author":"Singh","year":"2021","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"11","key":"2022100119165777800_CIT0012","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/cncr.30604","article-title":"Allogeneic hematopoietic cell transplantation for primary refractory acute lymphoblastic leukemia: a report from the Acute Leukemia Working Party of the EBMT","volume":"123","author":"Pavlu","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"2022100119165777800_CIT0013","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jamaoncol.2017.2380","article-title":"Salvage chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD for patients with relapsed or refractory philadelphia chromosome-negative acute lymphoblastic leukemia: a phase 2 clinical trial","volume":"4","author":"Jabbour","year":"2018","journal-title":"JAMA Oncol"},{"issue":"23","key":"2022100119165777800_CIT0014","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1200\/JCO.2010.28.8852","article-title":"Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure","volume":"28","author":"Duval","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"2022100119165777800_CIT0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"2022100119165777800_CIT0016","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"issue":"24","key":"2022100119165777800_CIT0017","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/10\/892\/46284867\/oyac163.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/27\/10\/892\/46284867\/oyac163.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T19:17:43Z","timestamp":1664651863000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/27\/10\/892\/6671773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":17,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,8,19]]},"published-print":{"date-parts":[[2022,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyac163","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,10,1]]},"published":{"date-parts":[[2022,8,19]]}}}